Benign and premalignant disease of the cervix

Slides:



Advertisements
Similar presentations
HPV Testing and Genotyping
Advertisements

Management of Abnormal Pap Smears and Cervical Dysplasia Jennifer L. Ragazzo, M.D. Department of Obstetrics and Gynecology Division of Womens Primary Healthcare.
MANAGEMENT OF ABNORMAL PAP SMEAR
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Cervical Cancer DR KHALID H. WALI SAIT (FRCSC) ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Updates on Pap Smear Guidelines 2014
Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.
Sample Taker Training Cervical Cytology & Management of Abnormalities.
Cervix Dr. Raid Jastania. Cervical Cancer Screening HPV infection Pre- Cancerous Dysplasia Cancer years.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
Cervical Cancer: Molecular Impact of an Infectious Disease.
Benign Conditions Of The Cervix Dr. Abdalla H. Elsadig MD.
HPV and cervical screening Test of cure
Screening for Cervical Cancer
Female Genital Tract 1-Vulva 2-Vagina 3-Cervix 4-Uterine corpus
Cervical Cancer Source: SEER’s Training Web Site
Cervical Cancer: Prevention and Treatment
Human Papilloma virus testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Human Papillomavirus? Human papilloma.
Diseases of cervix.
 Cervical cancer is a malignant tumour deriving from cells of the "cervix uteri", which is the lower part of uterus.  Begins in the lining of the cervix.
wrong to say cervical erosion -this condition appear at ( puberty ) ( pregnancy )
Screening for gynecological cancer
COLPOSCOPY Cervical Screening QARC Training School October 2012.
AN AUDIT OF PAP SMEAR, COLPOSCOPY AND HISTOLOGY RESULTS FROM IN TUNGARU CENTRAL HOSPITAL (KIRIBATI)
Cytopathology: Technique and Interpretation
Cervical Cancer Screening
Screening Tests for Brest & Cervical Cancer
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
CIN & Cervical Cancer Women ’ s Hospital, School of Medicine, Zhejiang university.
Screening for Cervical Cancer by Visual Inspection Techniques Dr Aruna Batra VMMC & SJH.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Cancer of Cervix Shashi. Sep-15 Introduction: Best example of cancer prevention. Best example of cancer prevention. Potentially curable if detected early.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
CIN and mimics Dr Michael Coutts Consultant Gynaecological Pathologist
Screening for Cervical Cancer Dr. Shanthi Manivannan, MD.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
Tumors of Cervix.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
Rajvinder Dhillon Specialist Biomedical Scientist & colposcopist
Cervical Intraepithelial Neoplasm
Cancer of Cervix Shashi. Oct-15 Introduction: Best example of cancer prevention. Best example of cancer prevention. US Statistics: US Statistics: Leading.
Adult Medical-Surgical Nursing
 Cervical cancer kills about women a year.  It’s the commonest cause of death from cancer in women.it’s the commonest after breast cancer. 
Cervical Cancer & Pap Smears
Premalignant lesions of the cervix. Applied anatomy.
CERVICAL SCREENING ANGELIKA KAUFMANN, ST4, UHCW, MEDICAL STUDENT INDUCTION, 2015.
COLPOSCOPY QUESTIONS Michael R. Downs M.D. October 2004.
NHS Cervical Screening Programme Introducing HPV triage and test of cure.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
Cervical Pathology Nilsa C. Ramirez, MD Director of Autopsy Pathology
HPV AND WOMEN’S CANCER A.C. Evans. M.D., Ph.D.. HPV and Women’s Cancer I have no relevant financial relationships with the manufacturer(s) of any commercial.
Dr. Ahmed jasim Ass.Prof.MBChB-DOG-FICMS COSULTANT OF GYN. & OBST. COSULTANT OF GYN. & OBST.
Cytopathology Feb
Cervical Cancer Screening NURS 541: Women’s Healthcare – Diagnosis and Management.
Chris Marshall Cardiff 4 th year Medical Student.
Understanding Test Results
HPV and Cervical Cancer Screening
CERVIX.
Cytology Codes & management Colposcopy- Management of cervical lesions
Cervical Cancer Colposcopy & Treatment
Cervical Cancer.
AGC&AIS Setareh Akhavan M.D Gynecologist Oncologist
Neoplasia of the cervix
SH-sheikhhasani Gyn-oncologist
Presentation transcript:

Benign and premalignant disease of the cervix Dr. Lubna maghur MRCOG

Introduction Benign diseases of the cervix are common and are unusually asymptomatic or cause minor symptoms but must be differentiated from malignancy. Cervical cancer is the second commonest cancer in women. It is proceeded by a premalignant form years before its invasion. Screening for premalignant disease of the cervix markedly reduces the deaths from cervical cancer.

objective To understand the normal cervical epithelium To be able to define metaplasia and dysplasia. To understand the concept of cervical screening. To outline the principles of colposcopy. To outline the management of CIN

Epithelium of the cervix

Transformational zone: The area of cervix between the old and new squamo- columnar junction. It is the area of risk of developing premalignant and malignant disease of the cervix.

Benign diseases of the cervix Cervical ectropion. Nabothian follicle. Genital warts.

Cervical ectropion (erosion) Physiological presence of columnar epithelium on the ectocervix. Increases in pregnancy and OCP. May lead to vaginal discharge and PCB. Management includes reassurance, exclude other cause, and if distressing coagulation.

Nabothian follicle Endocervical glands in the transformational zone become covered with squamous cells and forms mucus filled cysts.

Premalignant disease of the cervix HPV infection CIN I CIN II CIN III Cervical cancer Normal cervix

HPV infection DNA virus. Over 100 different types and subtypes of this virus. Common infection effecting epithelial surface. Genital HPV is divided into Low risk type (HPV 6,11) cause genital warts. High risk types (HPV 16, 18, 31, 33, 45, 56). HPV is a common infection while cervical cancer is a rare disease.

Factors that increase risk of transmission: Smoking. Increasing parity. Early age of intercourse. Oral contraceptive pills. Immunity.

Cervical intraepithelial neoplasia Metaplasia: change of epithelium from one cell lining (columnar) to another (squamous). Dysplasia: abnormal epithelial cells that fail to maturate. (hyperchromasia, larger, variable size, mitosis). it may be mild, moderate or severe

CIN 2 (moderate dysplasia) (severe dysplasia/CIS) Classification of CIN CIN1 Normal CIN 1 (condyloma) (mild dysplasia) CIN 2 (moderate dysplasia) CIN 3 (severe dysplasia/CIS) Invasive cancer Histology of squamous cervical epithelium1

Bethesda system Low grade squamous intraepithelial lesion (LSIL); HPV infection, CIN I. High grade squamous intraepithelial lesion (HSIL); CIN II, CIN III.

Outcome of CIN Spontaneous regression. Progression to invasive cancer. Progression from one stage to another takes years. Detection and treatment of CIN prevents cancer cervix.

Screening for CIN cervical smear Screening for dyskariosis by obtaining cervical cytology. Cervical screening should be carried out every 3-5 years in all sexually active women from 20-60 years of age. There is a 10-15 % chance of false positive or false negative results.

Management of cytology results Smear Risk of having HSIL Management If next smear is negative Normal 0.1% Repeat in 3-5 years Routine Inflammatory <6% Borderline 20-30% Repeat 6 months Repeat 1 year then 2 then routine. Colposcopy if 3 borderline. Mild dyskaryosis 30-50% Repeat in 3 months Or refer for colposcopy moderate dyskaryosis 50-70% Colposcopy Repeat after treatment Severe dyskaryosis 80-90% Invasion suspected 50% invasion Urgent colposcopy

Colposcopy Is the inspection of the cervix with a low powered microscope. Magnifies the cervix 4-20 times. The patient is put in lithotomy position. Passing a bivalve speculum gently into the vagina.

Inspection of the cervix and its vasculature. Green filter may help studying vasculature. Abnormal vascular structure includes punctuation and mosaicism. Acetic acid test: application of 3% acetic acid stained the abnormal area. The degree of staining correlates with severity of the lesion. Schiller test: application of Lugol’s iodine stains the normal cervix brown. Colposcopy gives a clinical diagnosis. Punch biopsy from the abnormal area gives a histopathological diagnosis.

Management of abnormal colposcopy CIN II,CIN III. ?CIN I. Techniques for treatment: Excisional: LLETZ, laser cone, knife cone, hysterectomy. Ablative: radical electrodiathermy, cold coagulation, cryocautery, laser. 90-95% cure rate

Adenocarcinoma insitu Less common than squamous intraepithelial neoplsia. Has same risk factors. Can not be reliably screened by colposcopy. Does not have particular colposcopic features. Divided into high grade and low grade. Characterized by skip lesions. Treatment by large cone biopsy.

Human papilloma virus vaccine The first vaccine that intends to prevent cancer. 2 forms of vaccine are available Bivalent 16, 18 Quadrevalent 6, 11, 16, 18. Now licensed in a number of countries.

Summary Benign diseases of cervix are harmless but malignancy should be excluded. Cervical intraepithelial neoplasia proceedes cancer cervix by years. Screening for CIN reduces mortality from cancer cervix. Those with positive screening test should be referred to colposcopy for diagnosis and treatment.